{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-24-000009","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.251546+00:00","generated_at":"2026-06-06T00:41:28.491623+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"West Pharma Q4 adj EPS flat YoY at $1.83; FY24 adj EPS guidance $7.50-$7.75 vs $8.08 in FY23","bullets":["Q4 net sales $732.0M (+3.3% YoY); full-year net sales $2.950B (+2.2% YoY).","Q4 reported EPS $1.83 (+34.6% YoY); full-year reported EPS $7.88 (+1.9% YoY).","FY24 guidance: net sales $3.000B-$3.025B; adjusted EPS $7.50-$7.75; organic sales growth ~2%-3%.","Proprietary Products organic sales down 0.3% Q4; COVID headwinds cited; excluding COVID, high-single-digit growth.","FY23 free cash flow $414.5M (down 5.7%); repurchased 1.27M shares for $438.3M at avg $346.34."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-24-000009","json":"https://secwatch.observer/filing/0000105770-24-000009.json","markdown":"https://secwatch.observer/filing/0000105770-24-000009.md","text":"https://secwatch.observer/filing/0000105770-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/wst-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:41:28.491623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76cf0ba3000fce080d327d06190fe61ee33885cf","claim":"WEST PHARMACEUTICAL SERVICES INC reported Full-year 2024 results: revenue in a range of $3.000 billion to $3.025 billion, EPS adjusted-diluted EPS in a range of $7.50 to $7.75. Guidance initiated.","evidence_excerpt":"The Company is introducing full-year 2024 financial guidance of net sales in a range of $3.000 billion to $3.025 billion and adjusted-diluted EPS in a range of $7.50 to $7.75.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-year 2024"},{"label":"Revenue","value":"in a range of $3.000 billion to $3.025 billion"},{"label":"EPS","value":"adjusted-diluted EPS in a range of $7.50 to $7.75"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"e00931739e170190963f79035e4425764e703729","claim":"WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2023 results: revenue $2.950 billion, EPS $7.88. Guidance reaffirmed.","evidence_excerpt":"full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) • Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth was 1.4%. Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%. • Fourth-quarter 2023 reported-diluted EPS","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth-quarter and full-year 2023"},{"label":"Revenue","value":"$2.950 billion"},{"label":"EPS","value":"$7.88"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e00931739e170190963f79035e4425764e703729","claim":"WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2023 results: revenue $2.950 billion, EPS $7.88. Guidance reaffirmed.","evidence_excerpt":"Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth-quarter and full-year 2023"},{"label":"Revenue","value":"$2.950 billion"},{"label":"EPS","value":"$7.88"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}